Trial Profile
A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2017
Price :
$35
*
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 15 May 2015 New trial record